SV investment has resulted in the approval of 24 novel therapeutics
SV News
9 January 2023Portfolio NewsImbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
9 January 2023Portfolio NewsTRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases- 9 January 2023Portfolio NewsExclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio
5 January 2023Portfolio NewsQurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
26 December 2022Portfolio NewsWhy a lucky few may help the rest of us beat disease
20 December 2022Portfolio NewsMestag Therapeutics appoints Prof. Ton Logtenberg as Chair
13 December 2022Portfolio NewsIn its largest single-asset purchase ever, Takeda snaps up TYK2 drug [from SV portfolio company, Nimbus] for $4B upfront- 13 December 2022Portfolio NewsTakeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
13 December 2022Portfolio NewsDementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases- 8 December 2022Portfolio NewsQurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
- 5 December 2022Portfolio NewsNinerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy
31 October 2022Portfolio NewsNitrase Therapeutics Presented Data on Role of Novel Nitrases in Regulating Known and Important Cancer Targets at EORTC-NCI-AACR Symposium
